Global Compact International Yearbook Ausgabe 2013

More documents

Recommendations

Info

sanofi WHO and Sanofi: A Public-Private Partnership to Save Lives For Sanofi, as a global healthcare partner, improving access to healthcare for the most disadvantaged patients is pivotal to its corporate social responsibility approach. At the core of this commitment is the long-term partnership with the World Health Organization (WHO) to control a group of debilitating infectious diseases, called “neglected tropical diseases,” which affect mostly poor people in developing countries. Since the partnership began, in 2001, more than 20 million people in sub-Saharan Africa have been screened for sleeping sickness, and more than 170,000 patients have received free treatment for what is a fatal disease, if left untreated. This partnership has put the elimination of sleeping sickness within reach – a prospect that was unthinkable a decade ago. By Benedict Blayney and Pierre-Guillaume Harscouët, Sanofi Dr. Pere Simarro, WHO, examining slides under the microscope for sleeping sickness parasites 162 Global Compact International Yearbook 2013
Good Practice Development Finger prick to collect blood for screening test Queuing for sleeping sickness screening test Sleeping sickness: A neglected tropical disease threatening millions of people in Africa More than one billion people worldwide are at risk from – or are affected by – a group of infectious tropical diseases that the international community considers to be “neglected diseases.” They are called “neglected” because the people who are most affected by these diseases are often the poorest populations, living in remote, rural areas, urban slums, and conflict zones with poor living and hygiene conditions. Neglected tropical diseases persist under conditions of poverty and are concentrated almost exclusively in the most disadvantaged populations in developing countries. Without a strong political voice to address the issue, these tropical diseases will continue to have a low profile and a low status in public health priorities, even though they are endemic in 149 countries and territories. Their consequences range – depending on the disease – from blindness, disfiguring scars and ulcers, severe pain, limb deformities, impaired mental and physical development, to death. Sleeping sickness (also known as human African trypanosomiasis) is a parasitic disease transmitted by the bite of an infected Glossina insect, commonly known as the tsetse fly. If left untreated, the parasites invade the central nervous system and cause severe symptoms such as changes in behavior, confusion, poor coordination, and disturbance of the sleep cycle (which gives the disease its name). Without treatment, sleeping sickness is generally fatal. Sleeping sickness threatens millions of people in 36 countries in sub-Saharan Africa. Many of the affected populations live in remote areas with limited access to adequate health services, making “Above all, this partnership shows what is possible when a pharmaceutical company wants to see its products make a difference in the lives of impoverished people living in remote places. In collaboration with WHO and national control programs, multiple challenges – beyond the donation of drugs – have been progressively tackled in ways that build sustainable capacity. The results speak for themselves.” Dr. Margaret Chan, Director-General of the World Health Organization surveillance, diagnosis, and treatment of the disease very challenging. In certain areas, displacement of populations due to conflict is an additional factor favoring transmission of the disease, in regions where health systems are weak or non-existent. A 1995 WHO Expert Committee estimated that 60 million people were at risk, with an estimated 300,000 new cases per year in Africa, of which fewer than 30,000 cases were diagnosed and treated. During epidemics, prevalence reached 50 percent in several villages in the Democratic Republic of the Congo, Angola, and Southern Sudan. Sleeping sickness was the first or second greatest cause of mortality in those communities, ahead of even HIV / AIDS. A partnership born from a desperate situation Despite the efforts of WHO, the situation for sleeping sickness was becoming desperate in 1999 when drugs to treat the disease were likely to be discontinued, and manufacturing to come to an end. However in 2000, discussions were initiated between WHO and Aventis, one of the parent companies of Sanofi, which manufactured three of the five drugs used to treat the disease (pentamidine, Global Compact International Yearbook 2013 163
Page 1 and 2:
we support Global Compact Internati
Page 3 and 4:
GC International Yearbook Greeting
Page 5 and 6:
Agenda Keynote /Keynote///Keynote//
Page 7 and 8:
GOOD PRACTICE Human Rights 74 Air F
Page 9 and 10:
Agenda Stakeholder Management STAKE
Page 11 and 12:
Agenda Stakeholder Management /Keyn
Page 13 and 14:
Agenda Stakeholder Management In th
Page 15 and 16:
Agenda Stakeholder Management Group
Page 17 and 18:
Agenda Stakeholder Management Stake
Page 19 and 20:
Agenda Stakeholder Management legit
Page 21 and 22:
Agenda Stakeholder Management (buff
Page 23 and 24:
Agenda Stakeholder Management tight
Page 25 and 26:
Agenda Stakeholder Management Respo
Page 27 and 28:
Agenda Stakeholder Management “
Page 29 and 30:
Agenda Stakeholder Management Multi
Page 31 and 32:
Agenda Climate Change Global Compac
Page 33 and 34:
Agenda Climate Change /Keynote///Ke
Page 35 and 36:
Agenda Climate Change Pressure on i
Page 37 and 38:
Agenda Climate Change lease the pan
Page 39 and 40:
Agenda Climate Change World 32,042
Page 41 and 42:
Agenda Climate Change change potent
Page 43 and 44:
Agenda Climate Change By Julie-Anne
Page 45 and 46:
Agenda Climate Change meet this nee
Page 47 and 48:
Agenda Climate Change So why are we
Page 49 and 50:
Agenda Climate Change Upcoming In a
Page 51 and 52:
Agenda CSR in Africa Global Compact
Page 53 and 54:
Agenda CSR in Africa though, has be
Page 55 and 56:
Agenda CSR in Africa investments ar
Page 57 and 58:
Agenda CSR in Africa World Cocoa Fo
Page 59 and 60:
Agenda CSR in Africa Selected Activ
Page 61 and 62:
Agenda CSR in Africa The problem is
Page 63 and 64:
Inside ... Agenda CSR in Africa aFr
Page 65 and 66:
Agenda CSR in Africa This is a sign
Page 67 and 68:
Agenda CSR in Africa By Prof. Bonni
Page 69 and 70:
Agenda CSR in Africa appropriate pu
Page 71 and 72:
98 74 168 110 76 136 80 100 170 130
Page 73 and 74:
Human Rights 74 76 80 82 84 86 88 9
Page 75 and 76:
Good Practice Human Rights The Air
Page 77 and 78:
Good Practice Human Rights Ever sin
Page 79 and 80:
Good Practice Human Rights In Augus
Page 81 and 82:
Good Practice Human Rights and cont
Page 83 and 84:
Good Practice Human Rights CCC Kaza
Page 85 and 86:
Good Practice Human Rights 1. All a
Page 87 and 88:
Good Practice Human Rights neighbor
Page 89 and 90:
Good Practice Human Rights The Chan
Page 91 and 92:
Good Practice Human Rights In 2004
Page 93 and 94:
Good Practice Human Rights their bu
Page 95 and 96:
Good Practice Human Rights Zinc is
Page 97 and 98:
Good Practice Human Rights artistic
Page 99 and 100:
Good Practice Labour Standards a co
Page 101 and 102:
Good Practice Labour Standards Bosc
Page 103 and 104:
Good Practice Labour Standards Seve
Page 105 and 106:
Good Practice Labour Standards Abov
Page 107 and 108:
Good Practice Labour Standards ecut
Page 109 and 110:
Environment 110 112 114 118 120 122
Page 111 and 112: Good Practice Environment Audi uses
Page 113 and 114: Good Practice Environment therefore
Page 115 and 116: Good Practice Environment time, we
Page 117 and 118: Good Practice Environment world in
Page 119 and 120: Good Practice Environment functions
Page 121 and 122: Good Practice Environment Furthermo
Page 123 and 124: Good Practice Environment “A cap
Page 125 and 126: Good Practice Environment Water2lif
Page 127 and 128: Good Practice Environment The geare
Page 129 and 130: Good Practice Environment ing effec
Page 131 and 132: Good Practice Anti-Corruption messa
Page 133 and 134: Good Practice Anti-Corruption A GLO
Page 135 and 136: CSR Management 136 140 142 144 148
Page 137 and 138: Good Practice CSR Management Reward
Page 139 and 140: Good Practice CSR Management Jan Sv
Page 141 and 142: Good Practice CSR Management Finall
Page 143 and 144: Good Practice CSR Management signed
Page 145 and 146: Good Practice CSR Management The MA
Page 147 and 148: Good Practice CSR Management 2000 l
Page 149 and 150: Good Practice CSR Management Concep
Page 151 and 152: Good Practice CSR Management of fou
Page 153 and 154: Good Practice Development Sustainab
Page 155 and 156: Good Practice Development Coop: Off
Page 157 and 158: Good Practice Development India acc
Page 159 and 160: Good Practice Development Above: Se
Page 161: Good Practice Development In this s
Page 165 and 166: Good Practice Development Mobile te
Page 167 and 168: Good Practice Development priate an
Page 169 and 170: Good Practice Financial Markets ris
Page 171 and 172: Good Practice Financial Markets Imp
Page 173 and 174: Good Practice Financial Markets We
Page 175 and 176: Agenda Integrated Reporting Global
Page 177 and 178: Agenda Integrated Reporting /Keynot
Page 179 and 180: Agenda Integrated ISO 26000 Reporti
Page 181 and 182: Agenda Integrated Reporting thereby
Page 193 and 194: GC International Yearbook Imprint A
Page 195 and 196: Previous Editions: This publication
show all

Global Compact International Yearbook Ausgabe 2013

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?